高危心脏手术患者围术期主动脉内球囊反搏的使用效果:一项随机临床试验
该单中心随机对照试验纳入181例高危择期冠状动脉旁路移植术患者,随机分为麻醉诱导后切皮前置入主动脉内球囊反搏组和无主动脉内球囊反搏组。主要终点为30天死亡和主要并发症(心源性休克、卒中、急性肾衰竭、纵隔炎、机械通气延长和再手术)的复合终点,主动脉内球囊反搏组发生率为47.8%,对照组为46.2%(p=0.46)。主动脉内球囊反搏组肌力药物使用中位时间(51小时 vs 39小时,p=0.007)和ICU停留时间(5天 vs 4天,p=0.035)均长于对照组。11项随机对照试验的荟萃分析证实,围术期主动脉内球囊反搏未能改善高危心脏手术患者的生存。
要点
- 在高危择期冠状动脉旁路移植术患者中,切皮前置入主动脉内球囊反搏组主要复合终点(30天死亡和主要并发症)发生率为47.8%,对照组为46.2%,差异无统计学意义(p=0.46)。
- 主动脉内球囊反搏组肌力药物使用中位时间为51小时(四分位距32-94小时),对照组为39小时(四分位距25-66小时),主动脉内球囊反搏组更长(p=0.007)。
- 主动脉内球囊反搏组ICU停留中位时间为5天(四分位距3-8天),对照组为4天(四分位距3-6天),主动脉内球囊反搏组更长(p=0.035)。
- 11项随机对照试验的荟萃分析证实,围术期主动脉内球囊反搏未能改善高危心脏手术患者的生存。
适用人群与场景
- 高危择期冠状动脉旁路移植术患者,平均(标准差)年龄65.4(9.4)岁,女性占32%。
处置流程与药物剂量
- 主动脉内球囊反搏组在麻醉诱导后、切皮前置入主动脉内球囊反搏;对照组不使用主动脉内球囊反搏。
研究设计与关键结果
- 单中心随机对照试验,纳入181例高危择期冠状动脉旁路移植术患者,随机分为切皮前主动脉内球囊反搏组和不使用主动脉内球囊反搏组。
- 主要终点为30天死亡和主要并发症(心源性休克、卒中、急性肾衰竭、纵隔炎、机械通气延长和再手术)的复合终点;主动脉内球囊反搏组43例(47.8%)发生主要终点事件,对照组42例(46.2%),p=0.46。
- 主动脉内球囊反搏组肌力药物使用中位时间51小时(四分位距32-94小时) vs 对照组39小时(四分位距25-66小时),p=0.007。
- 主动脉内球囊反搏组ICU停留中位时间5天(四分位距3-8天) vs 对照组4天(四分位距3-6天),p=0.035。
- 对11项随机对照试验的荟萃分析证实,围术期主动脉内球囊反搏未能改善高危心脏手术患者的生存。
证据类型、等级与局限
- 证据类型:单中心随机对照试验及随机对照试验的荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在高危择期冠状动脉旁路移植术患者中,围术期主动脉内球囊反搏未能降低30天死亡和主要并发症的复合终点,且与肌力药物使用时间和ICU停留时间延长相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to evaluate the efficacy of perioperative intra-aortic balloon pump use in high-risk cardiac surgery patients.
DESIGN: A single-center randomized controlled trial and a meta-analysis of randomized controlled trials.
SETTING: Heart Institute of São Paulo University.
PATIENTS: High-risk patients undergoing elective coronary artery bypass surgery.
INTERVENTION: Patients were randomized to receive preskin incision intra-aortic balloon pump insertion after anesthesia induction versus no intra-aortic balloon pump use.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was a composite endpoint of 30-day mortality and major morbidity (cardiogenic shock, stroke, acute renal failure, mediastinitis, prolonged mechanical ventilation, and a need for reoperation). A total of 181 patients (mean [SD] age 65.4 [9.4] yr; 32% female) were randomized. The primary outcome was observed in 43 patients (47.8%) in the intra-aortic balloon pump group and 42 patients (46.2%) in the control group (p = 0.46). The median duration of inotrope use (51 hr [interquartile range, 32-94 hr] vs 39 hr [interquartile range, 25-66 hr]; p = 0.007) and the ICU length of stay (5 d [interquartile range, 3-8 d] vs 4 d [interquartile range, 3-6 d]; p = 0.035) were longer in the intra-aortic balloon pump group than in the control group. A meta-analysis of 11 randomized controlled trials confirmed a lack of survival improvement in high-risk cardiac surgery patients with perioperative intra-aortic balloon pump use.
CONCLUSIONS: In high-risk patients undergoing cardiac surgery, the perioperative use of an intra-aortic balloon pump did not reduce the occurrence of a composite outcome of 30-day mortality and major complications compared with usual care alone.
参考来源
- Rocha Ferreira GS, de Almeida JP, Landoni G, et al. Effect of a Perioperative Intra-Aortic Balloon Pump in High-Risk Cardiac Surgery Patients: A Randomized Clinical Trial. Crit Care Med. 2018. PMID: 29727370. doi:10.1097/CCM.0000000000003185
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。